Sweeney Edward J Form 4 February 23, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

may continue. See Instruction

30(h) of the Investment Company Act of 1940 1(b).

(Middle)

(Print or Type Responses)

1. Name and Address of Reporting Person * Sweeney Edward J

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to Issuer

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

(Check all applicable)

(Last)

(First)

3. Date of Earliest Transaction

Director 10% Owner Other (specify

(Month/Day/Year)

02/19/2010

X_ Officer (give title below) below) Principal Accounting Officer

C/O ENDO PHARMACEUTICALS HOLDINGS INC., 100 ENDO

(Street)

BOULEVARD

4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

CHADDS FORD, PA 19317

(City) (State) (Zip) 2. Transaction Date 2A. Deemed

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)

(Month/Day/Year) Execution Date, if

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

5. Amount of Securities Beneficially Owned Following Reported Transaction(s)

(Instr. 3 and 4)

6. Ownership 7. Nature of Indirect Form: Direct (D) or Beneficial Indirect (I)

(Instr. 4)

Ownership (Instr. 4)

SEC 1474

(9-02)

Common

Stock, par value \$.01

per share

02/22/2010

M

695

Code V Amount

Price

(A)

(D)

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

695

Edgar Filing: Sweeney Edward J - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Ar Underlying Se (Instr. 3 and 4)
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title
2007 Stock Incentive Plan Restricted Stock Units(RSUs)	<u>(2)</u>	02/22/2010		M		695	02/22/2010	02/22/2010(3)	Common Stock
2007 Stock Incentive Plan Restricted Stock Units(RSUs)	<u>(2)</u>	02/19/2010		A	4,677		<u>(4)</u>	02/19/2014(4)	Common Stock
2007 Stock Incentive Plan Stock Options (6)	\$ 20.61	02/19/2010		A	13,276		<u>(7)</u>	02/19/2020	Common Stock

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Sweeney Edward J C/O ENDO PHARMACEUTICALS HOLDINGS INC. 100 ENDO BOULEVARD CHADDS FORD, PA 19317

Principal Accounting Officer

Signatures

/s/ Caroline B. Manogue, by Power of Attorney 02/23/2010

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

Edgar Filing: Sweeney Edward J - Form 4

- (1) This represents the vesting of restricted stock units granted to Mr. Sweeney on February 21, 2008. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- (2) Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- Twenty-five percent (25%) of Mr. Sweeney's February 21, 2008 grant of restricted stock units (RSUs) generally vest 25% on each of (3) February 21, 2009, February 21, 2010, February 21, 2011 and February 21, 2012. The 695 shown here is the amount that vested on February 22, 1010 (since February 21, 2010 was a Sunday). Upon vesting, we consider the underlying RSUs to be expired.
- (4) These restricted stock units (RSUs) generally vest 25% per year on each of February 19, 2011, February 19, 2012, February 19, 2013 and February 19, 2014. Upon vesting, we consider the underlying RSUs to be expired.
- (5) These securities were granted to Mr. Sweeney in consideration of his services as the Principal Accounting Officer of Endo Pharmaceuticals Holdings Inc.
- (6) Representing the right to buy shares of common stock, par value \$.01 per share, of Endo Pharmaceuticals Holdings Inc.
- (7) These stock options are generally exercisable 25% per year on each of February 19, 2011, February 19, 2012, February 19, 2013 and February 19, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.